Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: zolmitriptan

« Back to Dashboard
Zolmitriptan is the generic ingredient in three branded drugs marketed by Astrazeneca, Apotex Inc, Glenmark Generics, Jubilant Generics, Macleods Pharms Ltd, Zydus Pharms Usa Inc, Alembic Pharms Ltd, Invagen Pharms, Mylan Pharms Inc, Sun Pharma Global, Teva Pharms Usa, and IPR, and is included in seventeen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for zolmitriptan. Five suppliers are listed for this compound.

Summary for Generic Name: zolmitriptan

Tradenames:3
Patents:2
Applicants:12
NDAs:17
Drug Master File Entries: see list20
Suppliers / Packaging: see list22
Therapeutic Class:Antimigraine Agents

Clinical Trials for: zolmitriptan

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
Status: Recruiting Condition: Migraine

Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Status: Completed Condition: Migraine

ZAP, US. Zomig for Appropriate for Primary Care
Status: Completed Condition: Migraine

Zomig - Treatment of Acute Migraine Headache in Adolescents
Status: Completed Condition: Migraine Headache

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Status: Completed Condition: Migraine

Efficacy and Tolerability of Zolmitriptan Nasal Spray
Status: Completed Condition: Migraine

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
Status: Completed Condition: Acute Migraine; Migraine Headache; Headache Disorders

Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury
Status: Completed Condition: Spinal Cord Injuries; Muscle Spasticity

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Status: Completed Condition: Migraine

Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Status: Completed Condition: Migraine Disorders

Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy
Status: Completed Condition: Migraine Disorders

A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data
Status: Completed Condition: Migraine Disorders

Treximet ™ Pharmacy Budget Impact Model Database Validation Study
Status: Completed Condition: Migraine Disorders

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Status: Recruiting Condition: Workplace Migraine Treatment

Quality Improvement and Practice Based Research in Neurology Using the EMR
Status: Not yet recruiting Condition: Brain Tumors; Epilepsy; Migraine; Mild Cognitive Impairment; Concussion; Multiple Sclerosis; Neuropathy; Parkinson's; Restless Legs Syndrome; Stroke

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
ZOMIG-ZMT
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL021231-002Sep 17, 2001RXYes<disabled><disabled>
Macleods Pharms Ltd
ZOLMITRIPTAN
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL204336-002Oct 22, 2015RXNo<disabled><disabled>
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-004Sep 30, 2003RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: zolmitriptan

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-004Sep 30, 20035,466,699*PED<disabled>
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-002Nov 25, 19975,466,699*PED<disabled>
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-001Nov 25, 19975,863,935*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc